<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diamond-Blackfan anemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diamond-Blackfan anemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diamond-Blackfan anemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anupama Narla, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3427752807"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diamond-Blackfan anemia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F105650&amp;token=87jLzclRwWxNoI%2BQq5Gg75%2BfB3QW2LMQj4Zb7o%2B7TmOkY0XL%2FtPpFil0S%2F%2FmNn3O&amp;TOPIC_ID=131283" target="_blank">DBA</a>) is a congenital erythroid aplasia that classically presents in infancy. It is characterized by a progressive normochromic, usually macrocytic, anemia; congenital malformations (in approximately 50 percent of patients); and predisposition to cancer (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 1</a>).</p><p>The genetics, pathophysiology, clinical features, diagnosis, and management of DBA will be reviewed here. The use of hematopoietic cell transplantation (HCT) for treatment of DBA is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Diamond-Blackfan anemia'</a>.)</p><p>Other congenital and acquired pure red blood aplasias are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production"</a>.)</p><p class="headingAnchor" id="H3116777272"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Approximately 90 percent of patients with DBA are diagnosed within the first year of life, with 35 percent diagnosed within the first month [<a href="#rid1">1,2</a>]. In general, patients are significantly anemic at the time of presentation. Based on a report from the United Kingdom's registry, which identified 80 patients with DBA in a 20-year birth cohort, the estimated incidence of DBA is 5 cases per 1 million live births [<a href="#rid3">3</a>]. Males and females appear to be equally affected. Although most case reports are of White patients, the syndrome has been noted in different races and ethnic groups [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H2422290460"><span class="h1">GENETICS AND PATHOGENESIS</span></p><p class="headingAnchor" id="H2750992296"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>DBA is a ribosomopathy caused by genetic mutations affecting ribosome synthesis and processing. This results in stabilization and activation of the tumor protein p53 (TP53) tumor suppressor pathway, which is thought to be one of the causes of the clinical manifestations, including impaired erythropoiesis [<a href="#rid1">1,2,6,7</a>]. The erythropoietin level is consistently elevated in DBA because of ineffective erythropoiesis. However, relatively few erythropoietin receptors are available to bind erythropoietin, given the lack of erythroid precursors [<a href="#rid4">4</a>]. No evidence has been found for abnormalities in other regulators of erythropoiesis (eg, interleukin-3, granulocyte-macrophage colony-stimulating factor, or c-Kit or its ligand steel factor [also called stem cell factor]) [<a href="#rid8">8-10</a>]. (See  <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p class="headingAnchor" id="H3268013333"><span class="h2">Causative genetic variants</span><span class="headingEndMark"> — </span>Approximately 45 percent of DBA cases are familial, usually displaying autosomal dominant inheritance but with a wide range of severity within a family (ie, variable penetrance) [<a href="#rid11">11</a>]. Therefore, some cases that appear to be sporadic may prove to be familial if genetic testing is performed. In one series of 219 patients with DBA, 129 distinct mutations were found, 64 percent of which were de novo and 35 percent were inherited [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variants in genes encoding ribosomal proteins</strong> – The most common cause of DBA is a mutation in the gene encoding ribosomal protein 19 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603474&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp9OFimIamBqwV%2Bh8M3t%2BJC&amp;TOPIC_ID=131283" target="_blank">RPS19</a>), which is identified in approximately 25 percent of patients with DBA [<a href="#rid13">13</a>]. Other pathologic variants include mutations, deletions, and copy number variations in genes encoding the large (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F180468&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfjmmX14QGylCDpT81AUMQV%2F8QBuztzrt1HjUsdI9DU&amp;TOPIC_ID=131283" target="_blank">RPL35A</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603634&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr8niESZGoLJsGmnhvVBxdo&amp;TOPIC_ID=131283" target="_blank">RPL5</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604175&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrTGgOjt4h3LCO6DLfi1TIi&amp;TOPIC_ID=131283" target="_blank">RPL11</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603704&amp;token=87jLzclRwWxNoI%2BQq5Gg737BMH%2BWgiTgUsCDQqpKcnusRi2Jv5U3RfPD1eonncR2&amp;TOPIC_ID=131283" target="_blank"><i>RPL26</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F604174&amp;token=87jLzclRwWxNoI%2BQq5Gg765HJp4gseFHzyhwYcVAj42%2BXS7P9MKoviWdnuUC8kOF&amp;TOPIC_ID=131283" target="_blank"><i>RPL15</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F180466&amp;token=87jLzclRwWxNoI%2BQq5Gg72Bwd4mnR9YOIYz1n3IUnOrqySG5fZTIPWQiyLa3l7Ec&amp;TOPIC_ID=131283" target="_blank"><i>RPL19</i></a>) and small (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602412&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyq7KNQrIa1G%2FQV1jwij%2B8fo&amp;TOPIC_ID=131283" target="_blank">RPS24</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F180472&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfjmmX14QGylCDpT81AUMSF0zhkaa1khJXv6idi%2Fca%2F&amp;TOPIC_ID=131283" target="_blank">RPS17</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603658&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqQ64ez5Gn6zwlQFyp5e0%2BY&amp;TOPIC_ID=131283" target="_blank">RPS7</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603632&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypz0uaM2vtvDz%2B2ei7SVBTX&amp;TOPIC_ID=131283" target="_blank">RPS10</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603701&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrarpayndAtjOnMGObLSfe9&amp;TOPIC_ID=131283" target="_blank">RPS26</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603633&amp;token=87jLzclRwWxNoI%2BQq5Gg79CeLoxqMqJsMP%2Fi1tiT1HhqrU6fTe56ZAC3i%2BrUvdcW&amp;TOPIC_ID=131283" target="_blank">RPS29</a>) ribosomal subunits [<a href="#rid14">14-22</a>]. However, the list of potential candidate genes is ever evolving. Deletions and copy number variations may not be detected by sequencing [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other less common variants</strong> – While most cases of DBA are associated with variants in genes encoding ribosomal proteins, other genes have been implicated in a minority of cases:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations in the gene <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F305371&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6F4%2BYIZmRJWvRjw4VyFmeb1&amp;TOPIC_ID=131283" target="_blank"><i>GATA1</i></a> and the related chaperone gene, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601113&amp;token=87jLzclRwWxNoI%2BQq5Gg72Tx7uD9kXM15XGChV%2FD7xxoqxzhMh4L43AHpHopTFg9&amp;TOPIC_ID=131283" target="_blank"><i>HSP70</i></a>, have been reported to cause a DBA-like phenotype in a few patients [<a href="#rid1">1</a>]. <em>GATA1</em> is a transcription factor necessary for erythroid differentiation. One report identified <em>GATA1</em> mutations in three male patients with DBA [<a href="#rid25">25,26</a>]. Because two of the patients were siblings and the parents were unaffected, this suggests X-linked or autosomal recessive inheritance (in contrast with the ribosomal mutations described above, which typically have autosomal dominant inheritance). Notably, an identical mutation in <em>GATA1</em> can cause an X-linked form of dyserythropoietic anemia, as described separately. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Congenital dyserythropoietic anemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations and deletions in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607575&amp;token=87jLzclRwWxNoI%2BQq5Gg77btkOx%2FlaoZF2te%2F%2Fg9jnbiQu3Q96VtDWGIbaJUKWgr&amp;TOPIC_ID=131283" target="_blank"><i>CECR1</i></a> gene and the related chaperone gene, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300945&amp;token=87jLzclRwWxNoI%2BQq5Gg76gFKQE3KVwERKH1RXqOaxDT6v6slu8IC4NiwpVlpQWR&amp;TOPIC_ID=131283" target="_blank"><i>TSR2</i></a>, have been associated with a DBA-like phenotype [<a href="#rid21">21,27</a>]. <em>CECR1 </em>encodes the growth factor adenosine deaminase 2 (ADA2), and mutations and deletions in this gene are known to cause vasculopathy and inflammation [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/132472.html" rel="external">"Deficiency of adenosine deaminase 2 (DADA2)"</a>.)</p><p></p><p class="headingAnchor" id="H1303588164"><span class="h2">Genotype-phenotype correlation</span><span class="headingEndMark"> — </span>Genotype-phenotype correlations exist [<a href="#rid12">12,29,30</a>]. In a series of 74 patients with DBA, of whom 45 (61 percent) were identified as having ribosomal gene mutations, patients with <em>RPS19</em> mutations were more likely to maintain long-term steroid responsiveness without needing chronic transfusions [<a href="#rid30">30</a>]. The frequency and type of associated birth defects also varied depending on the genotype, with <em>RPL5</em> and <em>RPL11</em> mutations having a higher rate of birth defects compared with <em>RPS19</em> mutations. In a study of 45 patients with DBA, those with large deletions in <em>RPL35A</em> had a more severe phenotype (ie, more likely to have steroid-resistant anemia, neutropenia, craniofacial abnormalities, chronic gastrointestinal problems, and intellectual disabilities) compared with other pathogenic variants [<a href="#rid31">31</a>]. In another series of 24 patients with DBA associated with cleft palate, <em>RPL5</em> mutations were identified in 88 percent, whereas no patients had <em>RPS19</em> mutations [<a href="#rid12">12</a>].</p><p>Patients with combined features of DBA and mandibulofacial dysostosis (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F154500&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw9GOUvwZSDpMo1gtEJ2PM9w&amp;TOPIC_ID=131283" target="_blank">Treacher Collins syndrome</a>) may have pathogenic mutations in a single gene; however, this phenotype appears to be genetically heterogeneous [<a href="#rid27">27</a>]<em>.</em> (See  <a class="medical medical_review" href="/z/d/html/2926.html" rel="external">"Syndromes with craniofacial abnormalities", section on 'Treacher Collins syndrome'</a>.)</p><p class="headingAnchor" id="H2293080636"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>DBA usually presents in infancy. It is characterized by the following features [<a href="#rid32">32,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive anemia with onset in infancy or early childhood; anemia is normochromic (usually macrocytic) and is associated with reticulocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Normal cellularity of the bone marrow with markedly decreased or absent erythroid precursors</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital malformations (<a class="graphic graphic_table graphicRef67544" href="/z/d/graphic/67544.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of malignancies (see <a class="local">'Predisposition to cancer'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of endocrine dysfunction (see <a class="local">'Endocrine dysfunction'</a> below)</p><p></p><p class="headingAnchor" id="H2530980804"><span class="h2">Physical features</span><span class="headingEndMark"> — </span>Thirty to 50 percent of patients with DBA have associated congenital abnormalities [<a href="#rid3">3,4,13</a>]. These findings occur mainly in the head and upper limb area and include (<a class="graphic graphic_table graphicRef67544" href="/z/d/graphic/67544.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Craniofacial abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Neck anomalies</p><p class="bulletIndent1"><span class="glyph">●</span>Thumb anomalies</p><p class="bulletIndent1"><span class="glyph">●</span>Urogenital anomalies</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac anomalies (atrial and ventricular septal defects)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadism</p><p class="bulletIndent1"><span class="glyph">●</span>Intellectual disability</p><p class="bulletIndent1"><span class="glyph">●</span>Other skeletal abnormalities</p><p></p><p>Children with DBA sometimes have characteristic facial features with hypertelorism, flat nasal bridge, ear anomalies, and high-arched or cleft palate, similar to the features of Treacher Collins syndrome [<a href="#rid34">34,35</a>]. However, these features are quite variable. The name "Aase syndrome" has been used to describe patients with congenital anemia, triphalangeal thumbs, cleft lip-palate, and cardiac defects [<a href="#rid36">36,37</a>]. However, Aase syndrome is probably a variant of DBA rather than a distinct clinical entity [<a href="#rid38">38-40</a>].</p><p>The presence of physical anomalies does not reliably predict the severity of the hematologic disease [<a href="#rid3">3,5</a>]. However, as the understanding of genotype-phenotype correlations improves, this may change. (See <a class="local">'Genotype-phenotype correlation'</a> above.)</p><p>Growth failure or short stature occurs in &gt;30 percent of affected patients and may progress with age [<a href="#rid3">3,41,42</a>]. It is often associated with other congenital abnormalities. Primary growth failure is uncommon in children with <em>RPS19</em> gene mutations [<a href="#rid42">42</a>]. However, secondary growth failure can occur as a consequence of chronic glucocorticoid therapy. (See <a class="local">'Endocrine dysfunction'</a> below.)</p><p class="headingAnchor" id="H3815740249"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings in DBA include:</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – The anemia is generally normochromic and macrocytic (ie, elevated red blood cell mean corpuscular volume) and is usually profound at diagnosis. In one study, the mean hemoglobin (Hgb) was 6.5 g/dL in infants ≤2 months old and 4 g/dL in infants &gt;2 months old [<a href="#rid4">4,5</a>]. However, patients with nonclassical DBA may have only mild anemia or subtle erythroid abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocytopenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>White blood cell count is typically normal. Platelet counts are generally normal but can be increased or decreased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of stress erythropoiesis – Patients with DBA usually have an elevated fetal Hgb, and their red cells have increased expression of the i antigen beyond the first year of life. These fetal-like red blood cell features are indicative of stress erythropoiesis and persist even in patients with spontaneous remissions [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal bone marrow cellularity – Bone marrow examination shows normal overall cellularity with decreased or absent erythroid precursors. However, a report of 28 patients with steroid-refractory DBA who were followed for up to 13 years found that 75 percent ultimately developed moderate to severe bone marrow hypoplasia, with bone marrow cellularity ranging between 0 and 30 percent [<a href="#rid43">43</a>]. This hypoplasia correlated with the development of neutropenia and thrombocytopenia in 43 and 29 percent of the patients, respectively. None of the patients who were studied had cytogenetic abnormalities noted at the time of hypoplasia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated erythrocyte adenosine deaminase (eADA) activity – eADA activity is elevated in approximately 75 percent of patients with DBA who undergo such testing [<a href="#rid44">44-47</a>]. Although the significance of this finding is unclear, it may be useful in differentiating between DBA and transient erythroblastopenia of childhood (TEC) in ambiguous cases (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 1</a>). It may also be a useful marker to differentiate from other inherited bone marrow failure syndromes, in which eADA is not elevated [<a href="#rid48">48</a>]. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Transient erythroblastopenia of childhood'</a>.)</p><p></p><p class="headingAnchor" id="H3197573270"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>DBA should be suspected in infants and children presenting with severe anemia and reticulocytopenia during the first year of life.</p><p class="headingAnchor" id="H1969626347"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>While DBA is classically described as a progressive, severe anemia with onset in infancy, it is increasingly recognized that there is a wide phenotypic spectrum and more patients are being diagnosed at a later age. Thus, the diagnosis of DBA should be considered in any patient with an unexplained macrocytic anemia with reticulocytopenia after other etiologies have been ruled out. In addition, the diagnosis of DBA may be suspected based upon the presence of craniofacial or thumb abnormalities (<a class="graphic graphic_table graphicRef67544" href="/z/d/graphic/67544.html" rel="external">table 2</a>) in association with anemia.</p><p>The following sections review the approach to confirming the diagnosis of DBA. The diagnostic approach to evaluating anemia in children more broadly is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5927.html" rel="external">"Approach to the child with anemia"</a>.)</p><p class="headingAnchor" id="H3325992495"><span class="h3">Laboratory evaluation</span><span class="headingEndMark"> — </span>The laboratory evaluation for a patient with suspected DBA should include:</p><p class="bulletIndent1"><span class="glyph">●</span>A complete blood count with red blood cell indices and review of the peripheral blood smear</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of fetal hemoglobin (Hgb F; eg, by Hgb electrophoresis)</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte adenosine deaminase (eADA) activity</p><p></p><p>For patients requiring transfusion for the management of anemia, the above tests should be performed prior to transfusion.</p><p>This initial evaluation will help to establish whether the anemia is due to decreased red blood cell production and will help to distinguish between DBA, transient erythroblastopenia of childhood (TEC), and other causes of red cell aplasia. It also informs decisions about additional testing to perform (eg, genetic testing, bone marrow examination).</p><p class="headingAnchor" id="H3256610658"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>For patients with a high clinical suspicion of DBA, we suggest genetic testing for mutations in the genes associated with DBA. A list of laboratories that can perform this testing is available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=131283" target="_blank">Genetic Testing Registry website</a>. The available panels for DBA gene testing differ slightly regarding which genes are tested and the methodology used. The choice among them is dependent on clinician preference and insurance considerations. If a disease-causing mutation is found, the parents and siblings of the proband should be screened for the same mutation and should have routine laboratory testing (ie, complete blood count and reticulocyte count). Testing first-degree relatives is warranted even if they are asymptomatic to guide genetic counseling and determine the need for routine screening, given the increased risk for malignancy [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H571854672"><span class="h3">Bone marrow examination</span><span class="headingEndMark"> — </span>A bone marrow examination may be included in the diagnostic evaluation for suspected DBA; however, this practice is not standardized and varies from center to center. In some cases, the diagnosis of DBA can be made based upon a classic clinical history, consistent laboratory studies, and an identified <em>RP</em> gene mutation. In such cases, bone marrow examination adds little to the diagnostic evaluation, and some centers do not perform it unless the diagnosis is uncertain. The advantage of this approach is that it avoids procedure- and anesthesia-related risks in some patients. By contrast, other centers routinely perform bone marrow examination in all patients with suspected DBA to provide additional confirmation of the diagnosis and to serve as a baseline if concerns arise later for myelodysplastic syndrome (MDS).</p><p>If bone marrow examination is performed, the characteristic findings in DBA include normal bone marrow cellularity with markedly decreased or absent erythroid precursors. It is important to exclude the presence of ringed sideroblasts, which are seen in Pearson syndrome. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1264186751"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Diagnostic criteria for DBA were established by an international clinical consensus group in 2008 [<a href="#rid49">49</a>]. It should be noted that there have been substantial advances in the understanding of the genetics of DBA and in genetic testing since the initial consensus document. Nevertheless, these diagnostic criteria and categories remain the established tool for the diagnosis of DBA. Based on these criteria, the diagnosis of DBA can be established as follows (<a class="graphic graphic_table graphicRef131770" href="/z/d/graphic/131770.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic DBA</strong> – Classic DBA is diagnosed if <strong>all</strong> four diagnostic criteria are present:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Onset of anemia at age &lt;1 year</p><p class="bulletIndent2"><span class="glyph">•</span>Macrocytic anemia with no other significant cytopenias</p><p class="bulletIndent2"><span class="glyph">•</span>Reticulocytopenia</p><p class="bulletIndent2"><span class="glyph">•</span>Normal marrow cellularity with a paucity of erythroid precursors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonclassical DBA</strong> – A diagnosis of nonclassical DBA can be made if the patient has a DBA-associated genetic variant but does not meet all four diagnostic criteria for classic DBA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probable DBA</strong> – A probable diagnosis of DBA can be made based upon <strong>any</strong> of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Three of the four diagnostic criteria above plus a positive family history</p><p class="bulletIndent2"><span class="glyph">•</span>Two of the four diagnostic criteria above plus at least three minor criteria:</p><p class="bulletIndent3"><span class="glyph">-</span>Elevated eADA activity</p><p class="bulletIndent3"><span class="glyph">-</span>Congenital anomalies associated with DBA</p><p class="bulletIndent3"><span class="glyph">-</span>Elevated fetal Hgb</p><p class="bulletIndent3"><span class="glyph">-</span>No evidence of another inherited bone marrow failure syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Three or more minor criteria plus a positive family history</p><p></p><p class="headingAnchor" id="H3451184101"><span class="h2">Additional testing</span><span class="headingEndMark"> — </span>Once the diagnosis of DBA is confirmed, kidney ultrasound and echocardiography should be performed as a part of the initial evaluation because of the association of cardiac and kidney/urinary tract abnormalities in patients with DBA [<a href="#rid49">49</a>]. If there is clinical evidence of bony abnormalities, radiographs should be performed, but they are not otherwise routinely required. An ophthalmologic examination and an initial evaluation for endocrinopathies are appropriate prior to initiation of glucocorticoid therapy to establish a baseline.</p><p class="headingAnchor" id="H518665400"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes other causes of anemia due to decreased red blood cell production:</p><p class="bulletIndent1"><span class="glyph">●</span>Transient erythroblastopenia of childhood (TEC) is the most common cause of pure red blood cell aplasia in children and should be suspected in an otherwise healthy child with anemia and reticulocytopenia. TEC is a self-limited illness and typically presents between the ages of one and four years. Features that distinguish DBA from TEC are summarized in the table (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 1</a>). TEC is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Transient erythroblastopenia of childhood'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other genetic conditions characterized by bone marrow failure, including Fanconi anemia, Shwachman-Diamond syndrome, and dyskeratosis congenita, which usually have additional cytopenias. Routine testing for other bone marrow failure syndromes is not required unless there is diagnostic uncertainty, although evaluation for Fanconi anemia and dyskeratosis congenita is often done prior to possible hematopoietic stem cell transplant. (See  <a class="medical medical_review" href="/z/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Inherited genetic abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F557000&amp;token=tEpDslnpc0F0kICl%2Fz7sFVUH92jsKZBqveSwA4bma1KmVoRTM5qIGLTB3CSw0eQW&amp;TOPIC_ID=131283" target="_blank">Pearson marrow pancreas syndrome</a> is a relatively rare condition that shares a number of overlapping features with DBA. This condition can be diagnosed via mitochondrial DNA deletion testing. Clinical features are not always sufficient to distinguish these disorders. In a series of 173 genetically uncharacterized patients who were presumed to have DBA, eight patients (5 percent) harbored large mitochondrial deletions consistent with Pearson syndrome [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Pearson syndrome (large deletion of mitochondrial DNA)'</a>.)</p><p></p><p class="headingAnchor" id="H77341716"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H52355290"><span class="h2">Approach to treatment</span><span class="headingEndMark"> — </span>The mainstays of therapy for DBA are glucocorticoids and blood transfusion [<a href="#rid49">49</a>]. Hematopoietic cell transplantation (HCT) has been employed with success in steroid-refractory patients.</p><p>The general approach is as follows (<a class="graphic graphic_algorithm graphicRef131769" href="/z/d/graphic/131769.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Infants &lt;1 year old – Infants are maintained with transfusion therapy. Glucocorticoid therapy is generally deferred until after the age of one year because of the high risk of adverse effects of glucocorticoids in young infants. (See <a class="local">'Transfusion therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children ≥1 year old – For children ≥1 year old, we suggest glucocorticoid therapy as the first-line treatment. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Steroid-resistant patients – For patients who do not respond to or have unacceptable side effects from glucocorticoids, we suggest chronic transfusion therapy. HCT has been employed with success in steroid-refractory patients, as discussed separately. (See <a class="local">'Transfusion therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Diamond-Blackfan anemia'</a>.)</p><p></p><p class="bulletIndent1">Other agents previously used to treat patients with DBA (eg, androgens, <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">metoclopramide</a>, <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">cyclosporine</a>, other immunosuppressive agents) are generally not effective in steroid-resistant patients and are no longer routinely used. (See <a class="local">'Therapies not routinely used'</a> below.)</p><p></p><p class="headingAnchor" id="H428627673"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are the first-line therapy for DBA in children ≥1 year old. This therapy is generally deferred until after the age of one year because of the high risk of adverse effects of glucocorticoids in young infants [<a href="#rid49">49</a>]. The exact mechanism by which glucocorticoids stimulate erythropoiesis in DBA remains unknown. This is an area of ongoing investigation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – We usually begin with oral <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> at a dose of 2 mg/kg per day, administered as one or two daily doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to treatment</strong> – In steroid-responsive patients, reticulocytes typically begin to appear within one to two weeks in responders [<a href="#rid51">51</a>]. If there is no response after a four-week trial, glucocorticoid therapy should be discontinued [<a href="#rid49">49</a>]. The response rate to glucocorticoids in DBA ranges from 50 to 75 percent [<a href="#rid4">4,41</a>]. Factors associated with steroid responsiveness include [<a href="#rid41">41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older age at presentation</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of DBA</p><p class="bulletIndent2"><span class="glyph">•</span>Normal platelet count at the time of diagnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering</strong> – Once the hemoglobin (Hgb) has increased to ≥10 g/dL, a tapering schedule may be instituted, starting with a reduction in the number of daily doses. The steroid dose should be reduced slowly until a minimum effective dose is reached. Such minimally effective doses are highly variable, and many children who respond to steroids cannot be completely weaned [<a href="#rid4">4,5</a>]. The taper should be over an 8- to 12-week time period, with a goal of reaching a dose ≤0.5 mg/kg/day or ≤1 mg/kg every other day and a target Hgb between 8 and 10 g/dL [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection prophylaxis</strong> – Patients receiving prolonged steroid therapy should receive prophylaxis with sulfamethoxazole-trimethoprim. Live-virus vaccination should be avoided while the patient remains on high or moderate doses of corticosteroid therapy [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Contraindications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory patients</strong> – Steroid-resistant patients are generally managed with transfusion therapy (see <a class="local">'Transfusion therapy'</a> below). Other immunosuppressive agents (eg, cyclosporin) are generally not effective in steroid-resistant patients [<a href="#rid52">52,53</a>]. (See <a class="local">'Therapies not routinely used'</a> below.)</p><p></p><p class="bulletIndent1">Investigational therapies are discussed below (see <a class="local">'Investigational therapies'</a> below). The role of HCT in steroid-resistant transfusion-dependent patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Diamond-Blackfan anemia'</a>.)</p><p></p><p class="headingAnchor" id="H21375540"><span class="h2">Transfusion therapy</span><span class="headingEndMark"> — </span>Transfusion therapy is the mainstay of treatment for infants ≤12 months and patients who are refractory to or who have unacceptable side effects from glucocorticoid therapy. Patients are transfused to maintain Hgb levels 8 to 10 g/dL, which typically requires transfusion every four to six weeks [<a href="#rid49">49</a>]. Transfusions can also be used intermittently to support patients who are maintained on lowered doses of steroids as needed.</p><p>To avoid red cell sensitization and transfusion reactions, complete red cell typing should be performed and blood should be leukoreduced. (See  <a class="medical medical_review" href="/z/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Leukoreduced red blood cells'</a> and  <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">"Pretransfusion testing for red blood cell transfusion"</a>.)</p><p>Immediate family members should <strong>not</strong> be used as blood donors, to avoid allosensitization, which might jeopardize future HCT [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Donor'</a>.)</p><p>The major complication of transfusion therapy is iron overload, as discussed below. (See <a class="local">'Transfusional iron overload'</a> below.)</p><p class="headingAnchor" id="H3215056452"><span class="h2">Hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>HCT has been employed with success in steroid-refractory patients. The outcomes and timing of HCT for the treatment of this disease are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Diamond-Blackfan anemia'</a>.)</p><p class="headingAnchor" id="H2412957128"><span class="h2">Investigational therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L-leucine</strong> – Limited data on L-leucine in children with DBA suggest that it is safe and may increase weight and linear growth velocity in a subset of patients, though a hematologic response was less frequently observed [<a href="#rid55">55</a>]. The proposed mechanism is that L-leucine upregulates messenger RNA (mRNA) translation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing clinical trials</strong> – There are several ongoing clinical trials investigating the following agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sotatercept – Sotatercept acts as a ligand trap for members of the transforming growth factor-beta superfamily and inhibits negative regulators of late-stage erythropoiesis [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13074" href="/z/d/drug information/13074.html" rel="external">Trifluoperazine</a> – Trifluoperazine is a calmodulin inhibitor that is approved for use as an antipsychotic. It has been shown to increase Hgb levels in a mouse model of DBA, and it improved erythroid differentiation in human CD34+ cells in in vitro testing [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="108893" href="/z/d/drug information/108893.html" rel="external">Eltrombopag</a> – It is postulated that the thrombopoietin receptor agonist eltrombopag may improve production of red blood cells in DBA patients via chelation of iron and subsequent reduction in heme synthesis, resulting in decreased toxicity to bone marrow stem cells and developing erythroid cells [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene therapy</strong> – Gene therapy and gene editing have been proposed as possible future treatments for DBA, with some promising initial results in a mouse model [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H1579941503"><span class="h2">Therapies not routinely used</span><span class="headingEndMark"> — </span>Several drugs were previously used to treat DBA with limited effect and are no longer routinely used. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Androgens (which are occasionally used in Fanconi anemia and dyskeratosis congenita) (see  <a class="medical medical_review" href="/z/d/html/109777.html" rel="external">"Management and prognosis of Fanconi anemia", section on 'Androgens'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">Metoclopramide</a> [<a href="#rid61">61-63</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">Cyclosporine</a> and other immunosuppressive agents [<a href="#rid52">52</a>]</p><p></p><p class="headingAnchor" id="H4205109670"><span class="h1">LONG-TERM COMPLICATIONS</span></p><p class="headingAnchor" id="H745534740"><span class="h2">Predisposition to cancer</span><span class="headingEndMark"> — </span>DBA is associated with a predisposition to cancer. Associated malignancies include myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). There is also an increased risk of solid tumors including colon cancer, female genital cancers, and osteogenic sarcoma [<a href="#rid49">49,64</a>].</p><p>The risk of solid tumors in nontransplanted patients begins to rise around 30 years of age. The cancer risk is substantially higher than in a healthy population but is lower than that for Fanconi anemia or dyskeratosis congenita. However, the degree of risk for cancer has not been fully established and the optimal approach to cancer surveillance in this population is uncertain.</p><p>Our general approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance for MDS and AML – We monitor complete blood counts every three to six months (this is usually done in conjunction with monitoring of steroid therapy and/or chronic transfusions). If there are any changes in the complete blood count and/or a loss of response to therapy, we consider performing flow cytometry, including an MDS panel. Based on this and other clinical and laboratory findings, we determine if bone marrow examination is warranted. We do not routinely perform bone marrow surveillance in patients with DBA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance for solid tumors – We advise patients to undergo routine cancer screening, as recommended for all adults. We do not suggest more frequent or additional screening; however, we do counsel patients to maintain a high level of vigilance if any concerning symptoms arise. We encourage adult patients to establish appropriate specialty care (eg, with orthopedics, gastroenterology, and obstetrics/gynecology), ideally in the setting of a comprehensive bone marrow failure clinic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have undergone hematopoietic cell transplantation (HCT) – The risk of cancer in patients who undergo HCT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Cancer risk'</a>.)</p><p></p><p>In a report from a registry that included follow-up data on 608 patients with DBA, the cumulative incidence of malignancy (solid tumor or leukemia) was approximately 20 percent by age 46 years [<a href="#rid64">64</a>]. Four cases of MDS and two cases of AML were reported; solid tumors included colon cancer (n = 3), osteogenic sarcoma (n = 2), female genital cancers (n = 3), melanoma (n = 1), breast cancer (n = 2), non-Hodgkin lymphoma (n = 1), soft tissue sarcoma (n = 1), testicular cancer (n = 1), and choroid meningioma of the lung (n = 1).</p><p class="headingAnchor" id="H2550170902"><span class="h2">Endocrine dysfunction</span><span class="headingEndMark"> — </span>Endocrine dysfunction is common in patients with DBA, occurring in approximately 50 percent of patients [<a href="#rid32">32</a>]. Some of these complications are inherent to the disease, and some are secondary to chronic glucocorticoid therapy. Endocrine dysfunction may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Short stature – For children with DBA who have short stature, treatment with growth hormone may improve growth velocity and height for age [<a href="#rid65">65</a>]. However, there is some controversy about this, given the increased risk of osteosarcoma in these patients. There are no consensus guidelines, and decisions are ultimately made between the family, patient, and provider. This therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5843.html" rel="external">"Treatment of growth hormone deficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal insufficiency – Adrenal insufficiency is particularly common in patients who are chronically steroid dependent. Management of adrenal insufficiency is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadism. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D deficiency and bone disease. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a>.)</p><p></p><p>Given the frequency of endocrine abnormalities, we suggest that patients with DBA be seen annually by an endocrinologist for monitoring of growth velocity, pubertal development, vitamin levels, and thyroid function and other monitoring if on chronic steroids (eg, dual-energy x-ray absorptiometry [DXA] scans to screen for osteopenia).</p><p>In a report of 57 patients from the North American DBA registry, 53 percent of patients had at least one endocrine disorder, including adrenal insufficiency (32 percent), short stature (33 percent), hypogonadism (29 percent), hypothyroidism (14 percent), growth hormone dysfunction (7 percent), diabetes mellitus (2 percent), and diabetes insipidus (2 percent) [<a href="#rid32">32</a>]. Low levels of 25-hydroxyvitamin D were noted in one-half of the cohort. Adrenal insufficiency most commonly occurred in steroid-dependent patients, whereas other endocrinopathies were more often observed in chronically transfused patients.</p><p class="headingAnchor" id="H1776284266"><span class="h2">Transfusional iron overload</span><span class="headingEndMark"> — </span>Patients managed with chronic transfusion therapy are at risk for transfusional iron overload, which may result in significant morbidity and mortality. Patients with DBA appear to deposit iron differently compared with other patients who require chronic transfusions. For example, patients with DBA tend to develop earlier and more severe iron overload compared with patients with transfusion-dependent beta-thalassemia [<a href="#rid66">66</a>]. Thus, patients with transfusion-dependent DBA should be carefully monitored for this complication and iron chelation therapy should be instituted in patients with evidence of significantly increased iron stores. Iron chelation therapy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a> and  <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p class="headingAnchor" id="H3126411972"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Spontaneous remissions have been reported in as many as 25 percent of patients with DBA [<a href="#rid51">51</a>]. Overall, approximately 40 percent of patients are steroid dependent, 40 percent are transfusion dependent, and 20 percent go into remission by age 25 years [<a href="#rid42">42,49</a>]. In most cases, the remission is stable.</p><p>The prognosis for patients who undergo hematopoietic cell transplantation (HCT) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Post-HCT care'</a>.)</p><p class="headingAnchor" id="H3340799165"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – Diamond-Blackfan anemia (DBA) is a congenital red cell aplasia that usually presents in infancy or early childhood. It is a rare disorder with an estimated incidence of 5 cases per 1 million live births. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – The most common cause of DBA is a mutation in the gene encoding ribosomal protein 19 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603474&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp9OFimIamBqwV%2Bh8M3t%2BJC&amp;TOPIC_ID=131283" target="_blank">RPS19</a>), which is identified in approximately 25 percent of patients with DBA. Other pathologic variants have been identified, including mutations, deletions, and copy number variations in genes encoding the large and small ribosomal subunits. Other genes have been implicated in a minority of cases. (See <a class="local">'Genetics and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – The following laboratory findings are characteristic of DBA (see <a class="local">'Laboratory findings'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normochromic and usually macrocytic anemia associated with reticulocytopenia</p><p class="bulletIndent2"><span class="glyph">•</span>White blood cell and platelet counts are typically normal</p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of stress erythropoiesis (ie, elevated fetal hemoglobin [Hgb F] and increased expression of i red blood cell antigen)</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated erythrocyte adenosine deaminase (eADA)</p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow with normal cellularity with markedly decreased or absent erythroid precursors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical findings</strong> – Associated congenital abnormalities occur in up to 50 percent of patients with DBA, including (<a class="graphic graphic_table graphicRef67544" href="/z/d/graphic/67544.html" rel="external">table 2</a>) (see <a class="local">'Physical features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Craniofacial abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>Neck anomalies</p><p class="bulletIndent2"><span class="glyph">•</span>Thumb anomalies</p><p class="bulletIndent2"><span class="glyph">•</span>Urogenital anomalies</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiopulmonary anomalies</p><p class="bulletIndent2"><span class="glyph">•</span>Hypogonadism</p><p class="bulletIndent2"><span class="glyph">•</span>Intellectual disability</p><p class="bulletIndent2"><span class="glyph">•</span>Other skeletal abnormalities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The initial laboratory evaluation for a patient with suspected DBA includes the following and should be obtained prior to transfusion (see <a class="local">'Laboratory evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A complete blood count with red blood cell indices and smear review</p><p class="bulletIndent2"><span class="glyph">•</span>Reticulocyte count</p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of fetal Hgb (eg, by Hgb electrophoresis)</p><p class="bulletIndent2"><span class="glyph">•</span>eADA activity</p><p></p><p class="bulletIndent1">For patients with a high clinical suspicion of DBA, we suggest genetic testing for mutations in the genes associated with DBA. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Classic DBA is diagnosed if <strong>all</strong> of the following are present (see <a class="local">'Diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Onset of anemia at age &lt;1 year</p><p class="bulletIndent2"><span class="glyph">•</span>Macrocytic anemia with no other significant cytopenias</p><p class="bulletIndent2"><span class="glyph">•</span>Reticulocytopenia</p><p class="bulletIndent2"><span class="glyph">•</span>Normal marrow cellularity with a paucity of erythroid precursors</p><p></p><p class="bulletIndent1">A diagnosis of nonclassical DBA can be made if the patient has a DBA-associated gene mutation but does not meet diagnostic criteria for classic DBA. A probable diagnosis can be made based upon other supporting features, as summarized in the table (<a class="graphic graphic_table graphicRef131770" href="/z/d/graphic/131770.html" rel="external">table 3</a>). (See <a class="local">'Diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent1">Once the diagnosis of DBA is confirmed, additional testing includes kidney ultrasound and echocardiography to assess for associated congenital abnormalities. (See <a class="local">'Additional testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes transient erythroblastopenia of childhood (TEC) (<a class="graphic graphic_table graphicRef76264" href="/z/d/graphic/76264.html" rel="external">table 1</a>); other genetic bone marrow failure syndromes (eg, Fanconi anemia, Shwachman-Diamond syndrome, and dyskeratosis congenita), which usually have additional cytopenias; and Pearson marrow pancreas syndrome. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The mainstays of therapy for DBA are glucocorticoids and blood transfusion. Hematopoietic cell transplantation (HCT) has been employed with success in steroid-resistant patients. The general approach is as follows (<a class="graphic graphic_algorithm graphicRef131769" href="/z/d/graphic/131769.html" rel="external">algorithm 1</a>) (see <a class="local">'Treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &lt;1 year old - Infants are maintained with transfusion therapy. Glucocorticoid therapy is generally deferred until after the age of one year because of the high risk of adverse effects of glucocorticoids in young infants. (See <a class="local">'Transfusion therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children ≥1 year old - For children ≥1 year old, we suggest glucocorticoid therapy as the first-line treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The usual starting dose of oral <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> is 2 mg/kg per day, administered as one or two doses. In steroid-responsive patients, the response is usually apparent within one to two weeks, at which point, a tapering schedule can be started. Glucocorticoids are then tapered over 8 to 12 weeks, with a goal of reaching a dose ≤0.5 mg/kg/day or ≤1 mg/kg every other day and a target Hgb between 8 and 10 g/dL. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Steroid-resistant patients – For patients who do not respond to or have unacceptable side effects from glucocorticoids, we suggest chronic transfusion therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients are transfused to maintain Hgb levels ≥8 g/dL, which typically requires transfusion every four to six weeks. To avoid red cell sensitization and transfusion reactions, complete red cell typing should be performed and blood should be leukoreduced. HCT has been employed with success in steroid-resistant patients, as discussed separately. (See <a class="local">'Transfusion therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/132753.html" rel="external">"Hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS)", section on 'Diamond-Blackfan anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Approximately 40 percent of patients are steroid dependent, 40 percent are transfusion dependent, and 20 percent go into remission by age 25 years. In most cases, the remission is stable. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1">Long-term complications may include (see <a class="local">'Long-term complications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy – DBA is associated with a predisposition to cancer. Associated malignancies include acute myelogenous leukemia (AML); myelodysplastic syndrome (MDS); and solid tumors including colon cancer, female genital cancers, and osteogenic sarcoma. (See <a class="local">'Predisposition to cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endocrine dysfunction – Endocrine dysfunction is common in patients with DBA, including short stature, adrenal insufficiency, hypogonadism, hypothyroidism, vitamin D deficiency, and bone disease. Some of these complications are inherent to the disease, while others are caused by chronic glucocorticoid therapy. (See <a class="local">'Endocrine dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Iron overload – Patients managed with chronic transfusion therapy are at risk for transfusional iron overload. (See  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a> and  <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. Blood 2020; 136:1262.</a></li><li><a class="nounderline abstract_t">Da Costa L, Narla A, Mohandas N. An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia. F1000Res 2018; 7.</a></li><li><a class="nounderline abstract_t">Ball SE, McGuckin CP, Jenkins G, Gordon-Smith EC. Diamond-Blackfan anaemia in the U.K.: analysis of 80 cases from a 20-year birth cohort. Br J Haematol 1996; 94:645.</a></li><li><a class="nounderline abstract_t">Halperin DS, Freedman MH. Diamond-blackfan anemia: etiology, pathophysiology, and treatment. Am J Pediatr Hematol Oncol 1989; 11:380.</a></li><li class="breakAll">Alter B. Inherited bone marrow failure. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.280.</li><li><a class="nounderline abstract_t">Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011; 117:2567.</a></li><li><a class="nounderline abstract_t">Jaako P, Flygare J, Olsson K, et al. Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood 2011; 118:6087.</a></li><li><a class="nounderline abstract_t">Abkowitz JL, Broudy VC, Bennett LG, et al. Absence of abnormalities of c-kit or its ligand in two patients with Diamond-Blackfan anemia. Blood 1992; 79:25.</a></li><li><a class="nounderline abstract_t">Bagnara GP, Zauli G, Vitale L, et al. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia. Blood 1991; 78:2203.</a></li><li><a class="nounderline abstract_t">Sieff CA, Yokoyama CT, Zsebo KM, et al. The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3. Br J Haematol 1992; 82:640.</a></li><li><a class="nounderline abstract_t">Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity. Br J Haematol 2004; 125:243.</a></li><li><a class="nounderline abstract_t">Boria I, Garelli E, Gazda HT, et al. The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update. Hum Mutat 2010; 31:1269.</a></li><li><a class="nounderline abstract_t">van Dooijeweert B, van Ommen CH, Smiers FJ, et al. Pediatric Diamond-Blackfan anemia in the Netherlands: An overview of clinical characteristics and underlying molecular defects. Eur J Haematol 2018; 100:163.</a></li><li><a class="nounderline abstract_t">Cmejla R, Cmejlova J, Handrkova H, et al. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat 2007; 28:1178.</a></li><li><a class="nounderline abstract_t">Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet 2010; 86:222.</a></li><li><a class="nounderline abstract_t">Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet 2006; 79:1110.</a></li><li><a class="nounderline abstract_t">Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet 2008; 83:769.</a></li><li><a class="nounderline abstract_t">Farrar JE, Nater M, Caywood E, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood 2008; 112:1582.</a></li><li><a class="nounderline abstract_t">Mirabello L, Macari ER, Jessop L, et al. Whole-exome sequencing and functional studies identify RPS29 as a novel gene mutated in multicase Diamond-Blackfan anemia families. Blood 2014; 124:24.</a></li><li><a class="nounderline abstract_t">Wang R, Yoshida K, Toki T, et al. Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia. Br J Haematol 2015; 168:854.</a></li><li><a class="nounderline abstract_t">Ulirsch JC, Verboon JM, Kazerounian S, et al. The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet 2018; 103:930.</a></li><li><a class="nounderline abstract_t">Narla A, Yuan D, Kazerounian S, et al. A novel pathogenic mutation in RPL11 identified in a patient diagnosed with diamond Blackfan anemia as a young adult. Blood Cells Mol Dis 2016; 61:46.</a></li><li><a class="nounderline abstract_t">Farrar JE, Vlachos A, Atsidaftos E, et al. Ribosomal protein gene deletions in Diamond-Blackfan anemia. Blood 2011; 118:6943.</a></li><li><a class="nounderline abstract_t">Kuramitsu M, Sato-Otsubo A, Morio T, et al. Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia. Blood 2012; 119:2376.</a></li><li><a class="nounderline abstract_t">Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012; 122:2439.</a></li><li><a class="nounderline abstract_t">Rio S, Gastou M, Karboul N, et al. Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. Blood 2019; 133:1358.</a></li><li><a class="nounderline abstract_t">Gripp KW, Curry C, Olney AH, et al. Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28. Am J Med Genet A 2014; 164A:2240.</a></li><li><a class="nounderline abstract_t">Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370:911.</a></li><li><a class="nounderline abstract_t">Quarello P, Garelli E, Carando A, et al. Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica 2010; 95:206.</a></li><li><a class="nounderline abstract_t">Arbiv OA, Cuvelier G, Klaassen RJ, et al. Molecular analysis and genotype-phenotype correlation of Diamond-Blackfan anemia. Clin Genet 2018; 93:320.</a></li><li><a class="nounderline abstract_t">Gianferante MD, Wlodarski MW, Atsidaftos E, et al. Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in RPL35A. Haematologica 2021; 106:1303.</a></li><li><a class="nounderline abstract_t">Lahoti A, Harris YT, Speiser PW, et al. Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR). Pediatr Blood Cancer 2016; 63:306.</a></li><li class="breakAll">Bessler M, Mason PJ, Link DC, Wilson DB. Inherited bone marrow failure syndromes. In: Nathan and Oski's hematology and oncology of infancy and childhood, 8th ed, Orkin SH, Fisher DE, Ginsburg D, Look AT, Lux SE, Nathan DG (Eds), Saunders Elsevier, Philadelphia 2015. Vol 1, p.182.</li><li><a class="nounderline abstract_t">McFarren A, Jayabose S, Fevzi Ozkaynak M, et al. Cleft palate, bilateral external auditory canal atresia, and other midline defects associated with Diamond-Blackfan anemia: case report. J Pediatr Hematol Oncol 2007; 29:338.</a></li><li><a class="nounderline abstract_t">Ball S. Diamond Blackfan anemia. Hematology Am Soc Hematol Educ Program 2011; 2011:487.</a></li><li><a class="nounderline abstract_t">Aase JM, Smith DW. Congenital anemia and triphalangeal thumbs: a new syndrome. J Pediatr 1969; 74:471.</a></li><li><a class="nounderline abstract_t">Muis N, Beemer FA, van Dijken P, Klep-de Pater JM. The Aase syndrome. Case report and review of the literature. Eur J Pediatr 1986; 145:153.</a></li><li><a class="nounderline abstract_t">Alter BP. Thumbs and anemia. Pediatrics 1978; 62:613.</a></li><li><a class="nounderline abstract_t">Hurst JA, Baraitser M, Wonke B. Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities. Am J Med Genet 1991; 40:482.</a></li><li class="breakAll">Clinton C, Gazda HT. Diamond-Blackfan anemia. GeneReviews (internet). Available at: http://www.ncbi.nlm.nih.gov/books/NBK7047/.</li><li><a class="nounderline abstract_t">Willig TN, Niemeyer CM, Leblanc T, et al. Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Société d'Hématologie et d'Immunologie Pédiatrique (SHIP), Gesellshaft für Pädiatrische Onkologie und Hämatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI). Pediatr Res 1999; 46:553.</a></li><li><a class="nounderline abstract_t">Chen S, Warszawski J, Bader-Meunier B, et al. Diamond-blackfan anemia and growth status: the French registry. J Pediatr 2005; 147:669.</a></li><li><a class="nounderline abstract_t">Giri N, Kang E, Tisdale JF, et al. Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia. Br J Haematol 2000; 108:167.</a></li><li><a class="nounderline abstract_t">Glader BE, Backer K, Diamond LK. Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia. N Engl J Med 1983; 309:1486.</a></li><li><a class="nounderline abstract_t">Whitehouse DB, Hopkinson DA, Pilz AJ, Arredondo FX. Adenosine deaminase activity in a series of 19 patients with the Diamond-Blackfan syndrome. Adv Exp Med Biol 1986; 195 Pt A:85.</a></li><li><a class="nounderline abstract_t">Glader BE, Backer K. Elevated red cell adenosine deaminase activity: a marker of disordered erythropoiesis in Diamond-Blackfan anaemia and other haematologic diseases. Br J Haematol 1988; 68:165.</a></li><li><a class="nounderline abstract_t">Fargo JH, Kratz CP, Giri N, et al. Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia. Br J Haematol 2013; 160:547.</a></li><li><a class="nounderline abstract_t">Narla A, Davis NL, Lavasseur C, et al. Erythrocyte adenosine deaminase levels are elevated in Diamond Blackfan anemia but not in the 5q- syndrome. Am J Hematol 2016; 91:E501.</a></li><li><a class="nounderline abstract_t">Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol 2008; 142:859.</a></li><li><a class="nounderline abstract_t">Gagne KE, Ghazvinian R, Yuan D, et al. Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. Blood 2014; 124:437.</a></li><li><a class="nounderline abstract_t">Alter BP. Childhood red cell aplasia. Am J Pediatr Hematol Oncol 1980; 2:121.</a></li><li><a class="nounderline abstract_t">Leonard EM, Raefsky E, Griffith P, et al. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol 1989; 72:278.</a></li><li><a class="nounderline abstract_t">Singh AK, Radhakrishnan N, Seth T, et al. Diamond blackfan anemia: a tertiary care center experience. Mediterr J Hematol Infect Dis 2013; 5:e2013039.</a></li><li><a class="nounderline abstract_t">Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood 2010; 116:3715.</a></li><li><a class="nounderline abstract_t">Vlachos A, Atsidaftos E, Lababidi ML, et al. L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry. Pediatr Blood Cancer 2020; 67:e28748.</a></li><li class="breakAll">Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia (ACE-011-DBA). Study details available at: https://clinicaltrials.gov/ct2/show/NCT01464164 (Accessed on May 18, 2021).</li><li><a class="nounderline abstract_t">Taylor AM, Macari ER, Chan IT, et al. Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. Sci Transl Med 2020; 12.</a></li><li class="breakAll">The Use of Trifluoperazine in Transfusion Dependent DBA (DBA). Study details available at: https://clinicaltrials.gov/ct2/show/NCT03966053.</li><li class="breakAll">Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag. Study details available at: https://clinicaltrials.gov/ct2/show/NCT04269889 (Accessed on May 18, 2021).</li><li><a class="nounderline abstract_t">Jaako P, Debnath S, Olsson K, et al. Gene therapy cures the anemia and lethal bone marrow failure in a mouse model of RPS19-deficient Diamond-Blackfan anemia. Haematologica 2014; 99:1792.</a></li><li><a class="nounderline abstract_t">Abkowitz JL, Schaison G, Boulad F, et al. Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis. Blood 2002; 100:2687.</a></li><li><a class="nounderline abstract_t">Akiyama M, Yanagisawa T, Yuza Y, et al. Successful treatment of Diamond-Blackfan anemia with metoclopramide. Am J Hematol 2005; 78:295.</a></li><li><a class="nounderline abstract_t">Leblanc TM, Da Costa L, Marie I, et al. Metoclopramide treatment in DBA patients: no complete response in a French prospective study. Blood 2007; 109:2266.</a></li><li><a class="nounderline abstract_t">Vlachos A, Rosenberg PS, Atsidaftos E, et al. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood 2012; 119:3815.</a></li><li><a class="nounderline abstract_t">Howell JC, Joshi SA, Hornung L, et al. Growth hormone improves short stature in children with Diamond-Blackfan anemia. Pediatr Blood Cancer 2015; 62:402.</a></li><li><a class="nounderline abstract_t">Roggero S, Quarello P, Vinciguerra T, et al. Severe iron overload in Blackfan-Diamond anemia: a case-control study. Am J Hematol 2009; 84:729.</a></li></ol></div><div id="topicVersionRevision">Topic 131283 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702755" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30228860" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826887" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diamond-Blackfan anaemia in the U.K.: analysis of 80 cases from a 20-year birth cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694854" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diamond-blackfan anemia: etiology, pathophysiology, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694854" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diamond-blackfan anemia: etiology, pathophysiology, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068437" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989989" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1370205" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Absence of abnormalities of c-kit or its ligand in two patients with Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718488" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1282827" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15059149" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20960466" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114930" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pediatric Diamond-Blackfan anemia in the Netherlands: An overview of clinical characteristics and underlying molecular defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17647292" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116044" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17186470" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061985" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535205" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829207" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Whole-exome sequencing and functional studies identify RPS29 as a novel gene mutated in multicase Diamond-Blackfan anemia families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424902" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503522" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Genetic Landscape of Diamond-Blackfan Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27667165" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A novel pathogenic mutation in RPL11 identified in a patient diagnosed with diamond Blackfan anemia as a young adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045982" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ribosomal protein gene deletions in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262766" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22706301" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30700418" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942156" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552284" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early-onset stroke and vasculopathy associated with mutations in ADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19773262" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29044489" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Molecular analysis and genotype-phenotype correlation of Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32241839" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in RPL35A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26496000" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26496000" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483715" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cleft palate, bilateral external auditory canal atresia, and other midline defects associated with Diamond-Blackfan anemia: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160079" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diamond Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5764780" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Congenital anemia and triphalangeal thumbs: a new syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3732321" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Aase syndrome. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/714597" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Thumbs and anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746615" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746615" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Autosomal dominant transmission of congenital erythroid hypoplastic anemia with radial abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10541318" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Sociétéd'Hématologie et d'Immunologie Pédiatrique (SHIP), Gesellshaft für Pädiatrische Onkologie und Hämatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291361" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diamond-blackfan anemia and growth status: the French registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651740" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6646173" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3728189" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adenosine deaminase activity in a series of 19 patients with the Diamond-Blackfan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348976" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Elevated red cell adenosine deaminase activity: a marker of disordered erythropoiesis in Diamond-Blackfan anaemia and other haematologic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252420" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27556864" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Erythrocyte adenosine deaminase levels are elevated in Diamond Blackfan anemia but not in the 5q- syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671700" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24735966" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Childhood red cell aplasia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2503027" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23795277" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Diamond blackfan anemia: a tertiary care center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20651069" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : How I treat Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33025707" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33025707" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33087503" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33087503" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33087503" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25216681" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gene therapy cures the anemia and lethal bone marrow failure in a mouse model of RPS19-deficient Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351372" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15795909" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful treatment of Diamond-Blackfan anemia with metoclopramide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312003" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Metoclopramide treatment in DBA patients: no complete response in a French prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362038" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25492299" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Growth hormone improves short stature in children with Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19810012" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Severe iron overload in Blackfan-Diamond anemia: a case-control study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
